CJC-1295 No DAC & Ipamorelin: Research on Inflammation Markers

Research connecting CJC-1295 no DAC and ipamorelin to inflammation markers is early-stage, largely preclinical, and mixed in what it reports. Both compounds are studied as growth hormone secretagogues — CJC-1295 without DAC as a GHRH analog, ipamorelin as a selective ghrelin receptor agonist — and most of the inflammation-related work reaches them indirectly, through broader literature on the GH/IGF-1 axis and ghrelin receptor signaling rather than through head-to-head studies on the pair. For a business buyer, the practical takeaway is straightforward: there is genuine research interest, there is no settled conclusion, and these remain research-use-only compounds that cannot be marketed on an inflammation claim. What you can compete on is documentation.

Where the inflammation-marker literature actually sits

Inflammation markers are among the most commonly measured endpoints in biomedical research generally. Cytokine panels, C-reactive protein, interleukin-6, and TNF-alpha turn up as secondary endpoints across an enormous range of studies, which is part of why they appear in discussions of almost any signaling compound. Their presence in a paper does not mean the compound was studied for inflammation — often the marker was collected alongside the primary endpoint.

For these two peptides specifically, the honest summary is that direct, replicated evidence tying either compound to a defined change in a named inflammation marker is limited. Research on the growth hormone axis has examined immune and inflammatory endpoints for decades, and studies report context-dependent results that shift with model species, study duration, and the baseline state of the animals involved. Separately, ghrelin receptor signaling has been investigated for interactions with inflammatory pathways beyond growth hormone release, which is one reason ipamorelin appears in literature outside purely growth-related endpoints.

What does not exist is a consensus body of evidence supporting an inflammation-related outcome in humans for this pairing. Suppliers who summarize the field as settled are either reading secondary marketing copy or writing it. If your catalog or your staff repeats that framing, you inherit the exposure. The defensible position — and the one that holds up under scrutiny from a payment processor, a platform reviewer, or a regulator — is that the research is ongoing and the compounds are supplied for laboratory research use only.

Why researchers study a GHRH analog alongside a ghrelin mimetic

The pairing is common in the literature because the two compounds act on different receptors within the same axis. CJC-1295 no DAC is a modified GHRH fragment that binds the GHRH receptor. Ipamorelin is a pentapeptide that acts at the growth hormone secretagogue receptor, the same receptor family targeted by endogenous ghrelin. Because the pathways are distinct, researchers investigating growth hormone release frequently examine them in combination rather than isolation.

The 'no DAC' designation is worth understanding because buyers ask about it constantly. DAC refers to a Drug Affinity Complex, a modification described in the literature as substantially extending the circulating half-life of the molecule. The unmodified version is characterized by a much shorter half-life and a release profile closer to the body's natural pulsatile pattern. That difference is the entire reason the two variants are studied separately, and it is a legitimate, purely scientific distinction you can explain on a product page without straying into claims.

Ipamorelin is also described in research literature as comparatively selective within its class, with studies reporting limited effect on cortisol and prolactin in the models examined. That selectivity is why it shows up in study designs where researchers want to isolate a single pathway rather than confound their results. Again — this is compound science, not an outcome promise, and that distinction is exactly where most peptide marketing collapses.

What this means for the way your catalog describes these compounds

If you resell, the compliance risk in this category rarely comes from the compound. It comes from the copy. A product page that says a peptide supports recovery, reduces inflammation, or improves anything is a claim about a human outcome, and the compound is not approved for any human use. The safest catalog language describes what the molecule is, what receptor family it interacts with, and what researchers have investigated — hedged honestly with phrasing like research suggests or studies report.

Three practical habits keep a research-use catalog clean. First, separate the science from the promise: describe mechanism, never benefit. Second, train whoever answers your phone and your inbox, because verbal claims are claims. Third, keep research-use-only labeling and disclaimers consistent across product pages, packaging, invoices, and any wholesale documentation you pass along.

This also shapes which questions you should be prepared to decline. Customers will ask about preparation and amounts. Real Peptides does not supply dosing, titration, or preparation guidance for any compound, because these are research-use-only materials and that guidance would imply a human application that does not exist. The furthest a supplier should go is the concentration framework itself — milligrams of lyophilized peptide per vial, and how that relates to milligrams per milliliter at a given solvent volume. Anything past that math belongs to the qualified researcher, not the supplier.

What to verify before you commit to any supplier

Every wholesale peptide supplier will tell you their material is high purity. The difference between a supplier you can defend and one you cannot is whether you can check the claim yourself, per batch, without asking permission.

The COA question is the one that separates programs. Certificates of analysis sold separately, shown only to approved accounts, or presented as generic documents with no lot number are common in this market. A certificate you cannot tie to the vial in your hand is decoration.

Compliance questions worth putting to your own counsel

This section is informational and is not legal advice. The regulatory picture for research-use-only compounds is genuinely unsettled, and the honest guidance is to treat every question below as something to resolve with your attorney and, where relevant, your state licensing board — not something a supplier's blog can answer for you.

The questions worth raising: Does your business structure permit you to purchase and resell research-use-only materials in the states where you operate, and does any professional license you hold change that answer? How should research-use-only material be stored, labeled, and segregated from anything else you carry? What documentation should you retain about the source and lot of everything you resell, and for how long? What restrictions apply to how you advertise a research compound, including on platforms and in paid channels? And if you ship across state lines, which of those answers change?

Notice that none of these have a single national answer. Anyone who tells you a specific state permits or forbids a specific activity, without qualification, is guessing on your behalf. Get the answers in writing from someone who is accountable for them.

What Real Peptides does differently

Real Peptides supplies research-use-only compounds to businesses through its Wholesale Partner Program, and the program is built around the verification points above rather than around a sales conversation.

Every compound is tested to 99%+ HPLC purity, and each batch goes through seven-panel testing rather than spot checks on selected lots. Certificates of analysis are publicly verifiable — partners and their own customers can review the lab results directly instead of requesting a document and hoping one arrives. COAs are never a paid add-on. Fulfillment is US-based, with orders shipping in five to seven days, which matters when you are managing inventory against real demand rather than a forecast.

The wholesale application is three steps, and pricing tiers are presented as part of that process rather than held back for a negotiation. Both compounds discussed here are catalog items: CJC-1295 No DAC 10mg and Ipamorelin 10mg each carry their own batch documentation, so a partner stocking the pair can verify each lot independently.

What the program does not do is supply marketing claims. There is no outcome language, no protocol guidance, and no suggestion that any compound in the catalog is intended for human use. That constraint is the point — it is what makes the documentation worth something.

Deciding whether this belongs in your catalog

If you are evaluating growth hormone secretagogues for a research-use catalog, the deciding factors are supply consistency, verifiable testing, and whether the supplier's compliance posture matches your own risk tolerance. The inflammation-marker literature is interesting and unfinished; it is not a selling point, and treating it as one is the fastest way to create a problem you will pay a lawyer to unwind.

Businesses ready to review tier pricing and batch documentation can begin the three-step Wholesale Partner Program application at Real Peptides, where the current catalog, COAs, and program terms are available before any commitment is made.

Researchers and buyers comparing adjacent compounds can review the broader growth factor and tissue signaling research collection, explore the performance and recovery research category, or browse popular peptides for the compounds most frequently stocked by wholesale partners.